title: ErbB receptors and their growth factor ligands in pediatric intestinal inflammation.
abstract: The ErbB tyrosine kinases (epidermal growth factor receptor (EGFR), ErbB2/HER2, ErbB3, and ErbB4) are cell surface growth factor receptors widely expressed in many developing mammalian tissues, including in the intestinal tract. Signaling elicited by these receptors promotes epithelial cell growth and survival, and ErbB ligands have been proposed as therapeutic agents for intestinal diseases of pediatric populations, including inflammatory bowel disease (IBD), necrotizing enterocolitis (NEC), and inflammation associated with total parenteral nutrition (TPN). Furthermore, emerging evidence points to reduced ErbB ligand expression and thus reduced ErbB activity in IBD, NEC, and TPN models. This review will discuss the current understanding of the role of ErbB receptors in the pathogenesis and potential treatment of pediatric intestinal inflammation, with focus on the altered signaling in disease and the molecular mechanisms by which exogenous ligands are protective.
authors.affiliation: 1] Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, California [2] Department of Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Los Angeles, California [3] Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Frey
authors.affiliation: 1] Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, California [2] Department of Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Los Angeles, California [3] Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California.
authors.forename: D
authors.initials: D
authors.lastname: Brent Polk
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003092:Colitis / Q000378:metabolism; D003424:Crohn Disease / Q000378:metabolism; D004195:Disease Models, Animal; D015195:Drug Design; D020345:Enterocolitis, Necrotizing / Q000188:drug therapy / Q000378:metabolism*; D066246:ErbB Receptors / Q000187:drug effects / Q000378:metabolism*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000187:drug effects; D008024:Ligands; D058990:Molecular Targeted Therapy; D010289:Parenteral Nutrition, Total; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects / Q000378:metabolism*; D020893:Receptor, ErbB-3 / Q000187:drug effects / Q000378:metabolism*; D066247:Receptor, ErbB-4; D015398:Signal Transduction
chemical_list: D000893:Anti-Inflammatory Agents; D066246:ErbB Receptors; D005765:Gastrointestinal Agents; D008024:Ligands; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; D066247:Receptor, ErbB-4; C512478:EGFR protein, human; C508053:ERBB2 protein, human; C581292:ERBB3 protein, human; C587689:ERBB4 protein, human